Radiofrequency ablation of renal allograft cancer: Case report

Saitkarim Abdugafarov 1, Melss Assykbayev 1, Abylaikhan Sharmenov 1, Aygerim Kalzhan 2, Jamilya Saparbay 1 *
More Detail
1 Department of Oncohepatology, Gastroenterology and Organ Transplantation, National
2 Medical School, Medical University Astana, Nur-Sultan city, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 3, pp. 62-64.
Download Full Text (PDF)


Renal cell carcinoma (RCC) of an allograft kidney is an extremely rare type of neoplasm and accounts for about 0.22-0.5% of all kidney recipients. Kidney recipients undergo routine check-up, including ultrasound examination of the graft. RCC is often asymptomatic and can be an incidental finding on routine examination. In this case study, we describe a patient who developed clear cell carcinoma 9 months after the kidney transplantation from a living related donor. Radiofrequency ablation was chosen as the treatment option, considering small size solitary lesion in renal allograft. Complete ablative response was achieved after one treatment. In 4-year follow up period patient did not show any new or recurrent tumor. Radiofrequency ablation is a good therapeutic option for kidney allograft carcinoma.


Abdugafarov S, Assykbayev M, Sharmenov A, Kalzhan A, Saparbay J. Radiofrequency ablation of renal allograft cancer: Case report. J CLIN MED KAZ. 2021;18(3):62-4.


  • Penn I. Cancer in transplant recipients. Adv Ren Replace Ther 2000; 7(2):147-56.PMID:10782732
  • A.C.W. Chapman Jr and G. Wong, Cancer in the transplant recipient, Cold Spring Harb Perspect Med, vol. 3, no. 7, Article ID a015677, Jul 2013.
  • Favi E., Raison N., Ambrogi F., Delbue S. et al. Systematic review of ablative therapy for treatment of renal allograft neoplasms. World J Clin Cases 2019 September 6; 7(17): 2487-2504 doi: 10.12998/wjcc.v.ii7.2487
  • Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Caddedu JA. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma : comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 2012 ; 61 :1156-1161[PMID : 22257424 doi : 10.1016/j.eurro.2012.01.001]
  • Thompson RH, Atwell T, Schmitt G, Lohse CM, Kurup AN, Weisbrod A. et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-259 [PMID 25108580 doi: 10.1016/j.euroro.2014.07.2011]
  • Campbell S, Uzzo RG, Allaf ME, Bass EB, Caddedu JA, et al. Renal Mass and Localized Renal Cancer. AUA Guideline. J Urol 2017;198:520-529 [PMID: 28479239 doi: 10.1016/j.juro.2017.04.100
  • Vial T., Descotes J., Immunosuppressive drugs and cancer Toxicology. 2003 Apr 1; 185(3): 229-40. doi: 10.1016/s0300-483x (02)00612-1.
  • Martin P. Gallagher, Patrick J. Kelly, Meg Jardine, Vlado Perkovic, Alan Cass, Jonathan C. Craig, Josette Eris, Angela C. Webster. Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation J Am Soc Nephrol. 2010 May; 21(5): 852–858. doi: 10.1681/ASN.2009101043
  • Rao PS, Schaubel DE, Jia X, Li S, Port FK, Saran R. Survival on dialysis post-kidney transplant failure: results from the Scientific registry of Transplant Recipients. Am J Kidney Dis 2007; 49: 294-300 [PMID: 17261432 doi:10.1053/j.ajkd.2006.11.022
  • Chambade D, Meria P, Tariel E, Verine J, De Kerviler E, Peraldi MN, Glotz D, Desgrandchamps F, Mogniat-Artus P. Nephron-sparing surgery is a feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from a single center. J Urol 2008;180:2106-2109 [PMID:18804233 doi: 10.1016/j.juro.2008.07.055
  • Lowrance WT, Yee DS, Savage C, Cronin AM, Obrien MF, Donate SM,Vickers A, Russo P Complications after Radical and Partial Nephrectomy as a Function of Age J Urol. 2010 May: 183(5): 1725-1730 doi: 10.1016/j.juro.2009.12.101
  • Barama A, St-Louis G, Nicolet V,Hadjeres R, Daloze P Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 2005;5:3015-3018 [PMID: 16303018 doi: 10.1111/j.1600-6143.2005.01099.x]
  • Gervais D, McGovern FJ, Arellano RS, McDougl WS, Mueller PR Radiofrequency ablation of renal cell carcinoma: Part 1, Indications, Results, and Role in patient management over a 6-year period and ablation of 100 tumors AJR Am J Roentgenol. 2005 Jul; 185(1):64-71. doi: 10.2214/ajr.185.1.01850064